MRNA

Moderna
D

MRNA

38.260
USD
1.33
(3.59%)
Market Closed
Volume
362,449
EPS
-10
Div Yield
-
P/E
-2
Market Cap
14,706,992,108
OverviewSignalsIdeasNews
Signals
Related Instruments
    ABBV
    ABBV
    -4.630
    (-2.73%)
    171.713 USD
    AZN
    AZN
    -1.830
    (-2.81%)
    64.255 USD
    BMY
    BMY
    -2.270
    (-3.88%)
    56.230 USD
    B
    BNTX
    -3.740
    (-3.61%)
    99.740 USD
    GSK
    GSK
    -1.020
    (-2.97%)
    33.350 USD
    JNJ
    JNJ
    2.140
    (1.41%)
    155.48 USD
    MRK
    MRK
    -2.050
    (-2.08%)
    99.85 USD
    N
    NVAX
    0.12000
    (1.67%)
    7.32500 USD
    PFE
    PFE
    -1.225
    (-4.71%)
    25.14 USD
    REGN
    REGN
    -25.40
    (-3.25%)
    756.82 USD
    More
News

Title: Moderna

Sector: Healthcare
Industry: Biotechnology
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.